A record of what Bajaj Broking Analysis said publicly, with the source. Not advice.
“Bullish on Piramal Pharma, recommending a buying range of ₹193-203 with a 12-month target price of ₹229, indicating close to 16% upside. The stock is forming a base around its long-term 52-week EMA post-correction, providing a fresh entry opportunity with a favorable risk-reward setup. Biotech funding in the USA is improving, and its inhalation anaesthesia business is seeing demand uptick.”
Bajaj Broking Analysis’s track record (trackable calls only): 6 graded calls · 95% CI 61–100%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
Entry zone: ₹193–₹203. The call starts at the first close that comes into it.
Target ₹229, as stated.
Window: 12 months, the time frame the call states ("12-month").
Waiting for a close to reach the entry zone.
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.